<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2990">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637828</url>
  </required_header>
  <id_info>
    <org_study_id>GNS561-CL-I-Q-0291</org_study_id>
    <nct_id>NCT04637828</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection</brief_title>
  <acronym>CureCovid-2019</acronym>
  <official_title>Cure COVID: A Prospective, Controlled, Randomized Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genoscience Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genoscience Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate&#xD;
      the safety and efficacy profile of GNS561 in patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated either with oral GNS561 plus standard of care or only standard of&#xD;
      care. All patients in experimental arm will be treated for ten days. Study drug will be&#xD;
      provided as oral capsules containing 200 mg of GNS561. Patients will be followed-up during&#xD;
      hospitalization and after discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label, controlled, randomized phase 2 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number and proportion of participants, per randomized group, with a loss of one or two grades of National Early Warning Score (NEWS2) score at day-7 compared to baseline</measure>
    <time_frame>7 days</time_frame>
    <description>severe stage at baseline to medium or low stage at day-7 or medium stage at baseline to low stage at day-7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the 28-day survival rate</measure>
    <time_frame>28 days</time_frame>
    <description>the crude proportion of patients still alive 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of intensive care unit admission</measure>
    <time_frame>14 days</time_frame>
    <description>to 14 days from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of nasopharyngeal swab negativation at D7, D14 and D28</measure>
    <time_frame>7 days, 14 days and 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>GNS561 plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNS561</intervention_name>
    <description>study drug</description>
    <arm_group_label>GNS561 plus standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of COVID-19 (diagnostic test performed in a certified&#xD;
             laboratory).&#xD;
&#xD;
          -  Clinical status: Hospitalized for moderate COVID-19 with News2 score between 5 and 6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient known to have intolerance or hypersensitivity to chloroquine or any quinoline&#xD;
             derivates (quinine, tafenoquine, hydroxychloroquine, mefloquine).&#xD;
&#xD;
          -  History of QT prolongation (QTc ≥ 500 ms) or QTc ≥ 500msec at screening or bradycardia&#xD;
             &lt; 50/mn&#xD;
&#xD;
          -  Current use of loop diuretics and potassium supplementation or documented history of&#xD;
             hypokalemia or hypokalemia &lt; 3.5mmol/l at screening&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or solid organ transplant in the past.&#xD;
&#xD;
          -  Pregnant or breastfeeding patient, or expecting to conceive children within the&#xD;
             projected duration of the trial, starting with the screening visit through 6 months&#xD;
             after the last dose of study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>age 18 or older at the time of enrolment for women and age 60 or older at the time of enrolment for men.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genoscience Pharma</name>
      <address>
        <city>Marseille</city>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ansaldi, MD</last_name>
      <phone>+33(4) 91 26 99 50</phone>
      <email>cansaldi@genosciencepharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

